Search results
1 kwi 2021 · In this issue of Blood, Sarkozy et al 1 demonstrate that the genomic profile of B-cell lymphomas with features intermediate between diffuse large B-cell lymphoma (DLBCL) and classical Hodgkin lymphoma (CHL), often referred as gray zone lymphomas (GZLs), differs according to their topographic location in anterior mediastinum (thymic niche) or ...
- Clinical Features and Treatment Outcomes of Grey Zone Lymphoma (GZL ...
We conducted a comprehensive retrospective analysis of GZL...
- Selection of Treatment and Survival in Patients with Gray Zone Lymphoma ...
Gray-zone lymphoma (GZL) is a rare lymphoid neoplasm...
- Clinical Features and Treatment Outcomes of Grey Zone Lymphoma (GZL ...
Gray zone lymphoma is a very rare liquid malignancy that possesses intersecting features between primary mediastinal B-cell lymphoma and classic Hodgkin Lymphoma.
Gray zone lymphoma is a rare type of lymphoma that combines features of Hodgkin's lymphoma and large B-cell lymphoma. It often affects the mediastinum and has a poor prognosis.
2 lis 2023 · We conducted a comprehensive retrospective analysis of GZL patients treated in KroHem centers to evaluate clinical features, treatment outcomes and prognostic factors. GZL diagnoses were confirmed by a hematopathologist from a designated expert center, according to current WHO classification at time of diagnosis.
5 lis 2020 · Gray-zone lymphoma (GZL) is a rare lymphoid neoplasm initially described in 2005. The world health organization first recognized it as a separate entity in 2008. These tumors have intermediate morphologic and phenotypic features between diffuse large B-cell lymphoma and Hodgkin lymphoma.
1 kwi 2023 · Gray zone lymphoma is a rare type of lymphoma that is aggressive and often difficult to treat. It causes abnormal white blood cell growth and spread, along with swelling near the breastbone.
The morphology of gray zone lymphoma (GZL) is variable with tumor cells spanning the spectrum of diffuse large B-cell lymphoma (DLBCL) and classical Hodgkin lymphoma. The immunophenotype is frequently discordant.
